HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Oncology
Meta-analysis
Early time-of-day immune checkpoint inhibitor administration improves overall survival in advanced solid tumors
Cancer Patients Live Longer When Immunotherapy Starts Early in Day
This systematic review and meta-analysis evaluated 6129 patients with advanced solid tumors receiving immune checkpoint inhibitors. Earlier …
• Morning immunotherapy shots link to longer survival for advanced cancers • Helps patients fighting lung stomach kidney and other tough can…
May 5, 2026
Oncology
Meta-analysis
Neoadjuvant ICI plus chemotherapy improves event-free survival in early-stage TNBC
Adding immune drugs to chemo helps early stage triple negative breast cancer patients stay disease free longer
A meta-analysis found neoadjuvant immune checkpoint inhibitors with chemotherapy significantly improved event-free survival but not overall …
A large review of trials found that adding immune checkpoint inhibitors to chemotherapy improves survival chances for early stage triple neg…
May 5, 2026
Oncology
Meta-analysis
High tumour mutation burden improves overall survival in solid tumours treated with immune checkpoint inhibitors
High Mutation Counts May Predict Better Cancer Survival Outcomes
This systematic review and meta-analysis evaluated 5278 patients with solid tumours treated with immune checkpoint inhibitors or chemotherap…
High mutation counts in tumors may help predict who will survive longer when taking powerful immune-boosting cancer drugs
May 1, 2026
Pulmonology & Critical Care
Meta-analysis
Systematic review and meta-analysis shows immune checkpoint inhibitors improve survival in first-line ES-SCLC but not as single agents in second-line
Immune drugs boost survival in small-cell lung cancer
This systematic review and meta-analysis evaluates immune checkpoint inhibitors combined with chemotherapy versus chemotherapy alone for ext…
Adding immune checkpoint inhibitors to chemotherapy helps patients with extensive-stage small-cell lung cancer live longer.
May 1, 2026
Dermatology
Sys. Review
Systematic review of advancements and challenges in NK cell immunotherapy for malignancies
New NK cell therapies show promise for treating cancer
This systematic review evaluates Natural Killer (NK) cell immunotherapy, including CAR-NK, BiKEs, TriKEs, and CIML-NK cells, for hematologic…
New ways to use Natural Killer cells could help fight cancer while keeping the risk of dangerous immune reactions very low.
Frontiers
Apr 30, 2026
Oncology
Cohort
CT-based immune radiomic signature shows association with prognosis in non-small cell lung cancer
CT scans may help predict lung cancer treatment response
This cohort study utilized a CT-based immune radiomic signature, known as CT-RadScore, across multiple patient cohorts including TCIA, TCGA,…
A new way to analyze CT scans could help doctors predict how lung cancer patients respond to immunotherapy and other drugs.
Frontiers
Apr 30, 2026
Allergy & Immunology
Sys. Review
Review examines thoracic radiotherapy combined with chemoimmunotherapy for extensive-stage small cell lung cancer patients
Doctors are still figuring out the best way to treat extensive-stage small cell lung cancer
This review examines the use of thoracic radiotherapy combined with chemoimmunotherapy in patients with extensive-stage small cell lung canc…
A review notes that while combining radiation with chemotherapy and immune therapy helps some patients, the best approach is still being stu…
Frontiers
Apr 29, 2026
Allergy & Immunology
Sys. Review
Narrative review on ICIs in patients with viral infections and solid tumors
Cancer Immunotherapy Works Differently in Viral Infections
This narrative review synthesizes evidence on immune checkpoint inhibitors in patients with viral infections and solid tumors.
Cancer immunotherapy can still work—and sometimes even control viruses like hepatitis or HIV—but doctors must watch for dangerous flare-ups.
Frontiers
Apr 27, 2026
Oncology
Narrative review suggests time-related biases may attenuate apparent vaccine survival benefits in cancer patients
New math shows vaccine benefits in cancer care might be overstated
This narrative review and target trial emulation examines 3-year overall survival in cancer patients receiving COVID-19 vaccines versus thos…
A new look at the data reveals that timing errors made the vaccine look more powerful than it actually is for cancer patients.
medRxiv
Apr 26, 2026
Oncology
Cohort
CIPHER model predicts immune checkpoint inhibitor pneumonitis risk in non-small cell lung cancer patients
Lung Scans Can Now Predict Dangerous Side Effect Before Treatment
This cohort study evaluated a CIPHER model versus classical radiomic models for predicting immune checkpoint inhibitor-induced pneumonitis i…
This tool could help doctors protect patients before a serious side effect strikes.
medRxiv
Apr 24, 2026
Oncology
Sys. Review
Review of immunotherapy innovations for triple-negative breast cancer survival
New Hope for Tough-to-Treat Breast Cancer
This narrative review examines immunotherapy innovations, including immune checkpoint inhibitors and combination strategies, for patients wi…
This approach may change how doctors treat one of the hardest forms of breast cancer.
Frontiers
Apr 23, 2026
Allergy & Immunology
Sys. Review
Review of combination strategies for digestive system tumors including gastric and colorectal cancer
Unlocking New Ways to Beat Drug Resistance in Digestive Cancers
This review examines theoretical approaches to enhance efficacy in patients with digestive system tumors, including gastric, colorectal, and…
Researchers are finding better ways to combine treatments so drugs keep working longer.
Frontiers
Apr 23, 2026